Manager TitleAgeSince
Chief Executive Officer 55 12/10/2020
Director of Finance/CFO - 20/09/2023
Chief Tech/Sci/R&D Officer - 01/02/2020
Director TitleAgeSince
Chairman 84 01/03/2021
Chairman 55 01/02/2020
Director/Board Member 70 10/02/2020
Date Insider Type Main position Quantity % Market Cap.
09/01/24Buy

Director

91,325 0.0156%
20/02/23Others

Chief Executive Officer

50,941,666 8.7505%
20/02/23Others

Chief Executive Officer

50,941,666 8.7505%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-37.35% - - 101M
-0.48%+7.20%-5.08%+2.45% 46.36B
+0.45%+7.74%+376.63%+618.31% 37.88B
+1.76%+13.42%+20.34%-10.99% 31.12B
+0.34%+2.01%+8.94%+53.95% 30.61B
-4.16%-4.44%+8.53%+16.06% 24.69B
-1.48%+12.95% - - 16.25B
+0.48%+15.33%+71.29%+133.45% 14.85B
+1.00%+10.30%+13.31%+22.84% 13.58B
+2.03%+5.69%+101.63%+105.14% 12.95B
Average -0.74%+7.85%+74.45%+117.65% 25.36B
Weighted average by Cap. -0.14%+7.66%+83.49%+136.27%
Logo e-therapeutics plc
e-therapeutics plc is a United Kingdom-based company engaged in integrating computational power and biological data to discover life-transforming RNA interference (RNAi) medicines. The Company's technology uses computation to capture and model human biology, identify targets, and develop RNAi medicines against those targets that can be progressed to the clinic. Its HepNet platform enables the generation and analysis of biological network models, providing a mechanistic approach to drug discovery. Its RNAi platform, GalOmic, enables targeted delivery to hepatocytes in the liver and the specific silencing of disease-associated genes, identified by HepNet. The Company is progressing a pipeline of RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, hemophilia, and other undisclosed indications. Its pipeline includes ETX-312, ETX-407, ETX-148, ETX-291 and others.
Employees
40
  1. Stock Market
  2. Stocks
  3. ETPPF Stock